In this webinar, we explored the challenges facing orphan medicines and other innovative rare disease treatments looking to achieve market access in Europe. Orphan medicines and rare disease treatments are...
Are you looking to launch a new medical technology, medical or diagnostic device in the UK, Europe or North America? Would you like to know how health economic modelling could...
Are you looking for new ways to engage with healthcare professionals (HCPs)? Our Connected Insights dashboard can help you to build relationships with HCPs and decision makers, through meaningful engagements....
Partitioned survival analysis (PartSA) is currently the most commonly used modelling approach within HTA (health technology assessment) for advanced or metastatic cancers. However, until recently, there was no formal documentation...